Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

NCT03040986 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

NIH

Sponsor class

Conditions

KRAS NP_004976.2:p.G12R
Stage III Pancreatic Cancer AJCC v6 and v7
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Selumetinib Sulfate

Sponsor

National Cancer Institute (NCI)